Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection

Cell Host and Microbe

Volumn 19, Issue 6, 2016, Pages 800-813

  Henry Dunand, Carole J ^a   Leon, Paul E ^b   Huang, Min ^a   Choi, Angela ^b   Chromikova, Veronika ^b   Ho, Irvin Y ^a   Tan, Gene S ^b   Cruz, John ^c   Hirsh, Ariana ^b   Zheng, Nai Ying ^a   Mullarkey, Caitlin E ^b   Ennis, Francis A ^c   Terajima, Masanori ^c   Treanor, John J ^d   Topham, David J ^d   Subbarao, Kanta ^e   Palese, Peter ^b   Krammer, Florian ^b   Wilson, Patrick C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; EFFECTOR CELL; IMMUNIZATION; INFLUENZA A VIRUS (H7N9); MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS HEMAGGLUTINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE MODEL; DOG; FEMALE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFLUENZA, HUMAN; MDCK CELL LINE; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84973488141     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2016.05.014     Document Type: Article

References (54)

1. M.E. Ackerman, B. Moldt, R.T. Wyatt, A.S. Dugast, E. McAndrew, S. Tsoukas, S. Jost, C.T. Berger, G. Sciaranghella, Q. Liu, and et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples J. Immunol. Methods 366 2011 8 19
2. Y. Avnir, A.S. Tallarico, Q. Zhu, A.S. Bennett, G. Connelly, J. Sheehan, J. Sui, A. Fahmy, C.Y. Huang, G. Cadwell, and et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses PLoS Pathog. 10 2014 e1004103
3. T.M. Babu, M. Levine, T. Fitzgerald, C. Luke, M.Y. Sangster, H. Jin, D. Topham, J. Katz, J. Treanor, and K. Subbarao Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine Vaccine 32 2014 6798 6804
4. L. Baudino, Y. Shinohara, F. Nimmerjahn, J. Furukawa, M. Nakata, E. Martínez-Soria, F. Petry, J.V. Ravetch, S. Nishimura, and S. Izui Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions J. Immunol. 181 2008 6664 6669
5. H. Chen, H. Yuan, R. Gao, J. Zhang, D. Wang, Y. Xiong, G. Fan, F. Yang, X. Li, J. Zhou, and et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study Lancet 383 2014 714 721
6. Z. Chen, M. Baz, J. Lu, M. Paskel, C. Santos, K. Subbarao, H. Jin, and Y. Matsuoka Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets J. Virol. 88 2014 7016 7023
7. R.B. Couch, and J.A. Kasel Immunity to influenza in man Annu. Rev. Microbiol. 37 1983 529 549
8. R.B. Couch, S.M. Patel, C.L. Wade-Bowers, and D. Niño A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine PLoS ONE 7 2012 e49704
9. R.J. Cox, A.S. Madhun, S. Hauge, H. Sjursen, D. Major, M. Kuhne, K. Höschler, M. Saville, F.R. Vogel, W. Barclay, and et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine Vaccine 27 2009 1889 1897
10. D.J. DiLillo, G.S. Tan, P. Palese, and J.V. Ravetch Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo Nat. Med. 20 2014 143 151
11. D.J. DiLillo, P. Palese, P.C. Wilson, and J.V. Ravetch Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection J. Clin. Invest. 126 2016 605 610
12. C. Dreyfus, N.S. Laursen, T. Kwaks, D. Zuijdgeest, R. Khayat, D.C. Ekiert, J.H. Lee, Z. Metlagel, M.V. Bujny, M. Jongeneelen, and et al. Highly conserved protective epitopes on influenza B viruses Science 337 2012 1343 1348
13. D.C. Ekiert, G. Bhabha, M.A. Elsliger, R.H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I.A. Wilson Antibody recognition of a highly conserved influenza virus epitope Science 324 2009 246 251
14. D.C. Ekiert, R.H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H.J. Korse, B. Brandenburg, and et al. A highly conserved neutralizing epitope on group 2 influenza A viruses Science 333 2011 843 850
15. R.H. Friesen, P.S. Lee, E.J. Stoop, R.M. Hoffman, D.C. Ekiert, G. Bhabha, W. Yu, J. Juraszek, W. Koudstaal, M. Jongeneelen, and et al. A common solution to group 2 influenza virus neutralization Proc. Natl. Acad. Sci. USA 111 2014 445 450
16. J.S. Gach, C.J. Achenbach, V. Chromikova, B. Berzins, N. Lambert, G. Landucci, D.N. Forthal, C. Katlama, B.H. Jung, and R.L. Murphy HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study PLoS ONE 9 2014 e85371
17. R. Gao, B. Cao, Y. Hu, Z. Feng, D. Wang, W. Hu, J. Chen, Z. Jie, H. Qiu, K. Xu, and et al. Human infection with a novel avian-origin influenza A (H7N9) virus N. Engl. J. Med. 368 2013 1888 1897
18. E. García-García, and C. Rosales Signal transduction during Fc receptor-mediated phagocytosis J. Leukoc. Biol. 72 2002 1092 1108
19. P.H. Goff, F. Krammer, R. Hai, C.W. Seibert, I. Margine, A. García-Sastre, and P. Palese Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin J. Virol. 87 2013 8235 8240
20. J.L. Halliley, S. Khurana, F. Krammer, T. Fitzgerald, E.M. Coyle, K.Y. Chung, S.F. Baker, H. Yang, L. Martínez-Sobrido, J.J. Treanor, and et al. High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine J. Infect. Dis. 212 2015 1270 1278
21. F. He, M. Prabakaran, Y. Tan, K. Indira, S.R. Kumar, and J. Kwang Development of dual-function ELISA for effective antigen and antibody detection against H7 avian influenza virus BMC Microbiol. 13 2013 219
22. C.J. Henry Dunand, P.E. Leon, K. Kaur, G.S. Tan, N.Y. Zheng, S. Andrews, M. Huang, X. Qu, Y. Huang, M. Salgado-Ferrer, and et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains J. Clin. Invest. 125 2015 1255 1268
23. J. Hu, Y. Zhu, B. Zhao, J. Li, L. Liu, K. Gu, W. Zhang, H. Su, Z. Teng, S. Tang, and et al. Limited human-to-human transmission of avian influenza A(H7N9) virus, Shanghai, China, March to April 2013 Euro Surveill. 19 2014 Published online June 26, 2014
24. S. Jegaskanda, E.R. Job, M. Kramski, K. Laurie, G. Isitman, R. de Rose, W.R. Winnall, I. Stratov, A.G. Brooks, P.C. Reading, and S.J. Kent Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies J. Immunol. 190 2013 1837 1848
25. S. Jegaskanda, K.L. Laurie, T.H. Amarasena, W.R. Winnall, M. Kramski, R. De Rose, I.G. Barr, A.G. Brooks, P.C. Reading, and S.J. Kent Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1 J. Infect. Dis. 208 2013 1051 1061
26. S. Jegaskanda, J.T. Weinfurter, T.C. Friedrich, and S.J. Kent Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques J. Virol. 87 2013 5512 5522
27. R.A. Karron, K. Talaat, C. Luke, K. Callahan, B. Thumar, S. Dilorenzo, J. McAuliffe, E. Schappell, A. Suguitan, K. Mills, and et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults Vaccine 27 2009 4953 4960
28. K. Kaur, M. Sullivan, and P.C. Wilson Targeting B cell responses in universal influenza vaccine design Trends Immunol. 32 2011 524 531
29. F. Krammer, and P. Palese Influenza virus hemagglutinin stalk-based antibodies and vaccines Curr. Opin. Virol. 3 2013 521 530
30. F. Krammer, and P. Palese Advances in the development of influenza virus vaccines Nat. Rev. Drug Discov. 14 2015 167 182
31. F. Krammer, R.A. Albrecht, G.S. Tan, I. Margine, R. Hai, M. Schmolke, J. Runstadler, S.F. Andrews, P.C. Wilson, R.J. Cox, and et al. Divergent H7 immunogens offer protection from H7N9 virus challenge J. Virol. 88 2014 3976 3985
32. F. Krammer, A. Jul-Larsen, I. Margine, A. Hirsh, H. Sjursen, M. Zambon, and R.J. Cox An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans Clin. Vaccine Immunol. 21 2014 1153 1163
33. G.M. Li, C. Chiu, J. Wrammert, M. McCausland, S.F. Andrews, N.Y. Zheng, J.H. Lee, M. Huang, X. Qu, S. Edupuganti, and et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells Proc. Natl. Acad. Sci. USA 109 2012 9047 9052
34. I. Margine, P. Palese, and F. Krammer Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system J. Vis. Exp. 2013 10.3791/51112 Published online November 6, 2013
35. M.J. Mulligan, D.I. Bernstein, P. Winokur, R. Rupp, E. Anderson, N. Rouphael, M. Dickey, J.T. Stapleton, S. Edupuganti, P. Spearman, et al. DMID 13-0032 H7N9 Vaccine Study Group Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial JAMA 312 2014 1409 1419
36. M.B. Overdijk, S. Verploegen, A. Ortiz Buijsse, T. Vink, J.H. Leusen, W.K. Bleeker, and P.W. Parren Crosstalk between human IgG isotypes and murine effector cells J. Immunol. 189 2012 3430 3438
37. L. Pappas, M. Foglierini, L. Piccoli, N.L. Kallewaard, F. Turrini, C. Silacci, B. Fernandez-Rodriguez, G. Agatic, I. Giacchetto-Sasselli, G. Pellicciotta, and et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations Nature 516 2014 418 422
38. L. Rudenko, I. Kiseleva, A.N. Naykhin, M. Erofeeva, M. Stukova, S. Donina, G. Petukhova, M. Pisareva, V. Krivitskaya, M. Grudinin, and et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine PLoS ONE 9 2014 e87962
39. F. Schmeisser, A. Vasudevan, S. Verma, W. Wang, E. Alvarado, C. Weiss, V. Atukorale, C. Meseda, and J.P. Weir Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge PLoS ONE 10 2015 e0117108
40. K. Smith, L. Garman, J. Wrammert, N.Y. Zheng, J.D. Capra, R. Ahmed, and P.C. Wilson Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen Nat. Protoc. 4 2009 372 384
41. M. Sobhanie, Y. Matsuoka, S. Jegaskanda, T. Fitzgerald, R. Mallory, Z. Chen, C. Luke, J. Treanor, and K. Subbarao Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against H7N9 influenza J. Infect. Dis. 213 2015 922 929
42. K.R. Talaat, R.A. Karron, K.A. Callahan, C.J. Luke, S.C. DiLorenzo, G.L. Chen, E.W. Lamirande, H. Jin, K.L. Coelingh, B.R. Murphy, and et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults Vaccine 27 2009 3744 3753
43. G.S. Tan, F. Krammer, D. Eggink, A. Kongchanagul, T.M. Moran, and P. Palese A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo J. Virol. 86 2012 6179 6188
44. G.S. Tan, P.S. Lee, R.M. Hoffman, B. Mazel-Sanchez, F. Krammer, P.E. Leon, A.B. Ward, I.A. Wilson, and P. Palese Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin J. Virol. 88 2014 13580 13592
45. M. Terajima, M.D. Co, J. Cruz, and F.A. Ennis High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children J. Infect. Dis. 212 2015 1052 1060
46. J.J. Treanor, J.D. Campbell, K.M. Zangwill, T. Rowe, and M. Wolff Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine N. Engl. J. Med. 354 2006 1343 1351
47. T. Watanabe, M. Kiso, S. Fukuyama, N. Nakajima, M. Imai, S. Yamada, S. Murakami, S. Yamayoshi, K. Iwatsuki-Horimoto, Y. Sakoda, and et al. Characterization of H7N9 influenza A viruses isolated from humans Nature 501 2013 551 555
48. P.C. Wilson, and S.F. Andrews Tools to therapeutically harness the human antibody response Nat. Rev. Immunol. 12 2012 709 719
49. T.J. Wohlbold, V. Chromikova, G.S. Tan, P. Meade, F. Amanat, P. Comella, A. Hirsh, and F. Krammer Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8 influenza virus infection in mice J. Virol. 90 2015 851 861
50. T.J. Wohlbold, A. Hirsh, and F. Krammer An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13 Vaccine 33 2015 1102 1106
51. World Health Organization (2014). Influenza (seasonal) fact sheet. http://www.who.int/mediacentre/factsheets/fs211/en/.
52. World Health Organization (2015). WHO risk assessment of human infection with avian influenza A(H7N9) virus. http://www.who.int/influenza/human-animal-interface/influenza-h7n9/Risk-Assessment/en/.
53. J. Wrammert, K. Smith, J. Miller, W.A. Langley, K. Kokko, C. Larsen, N.Y. Zheng, I. Mays, L. Garman, C. Helms, and et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus Nature 453 2008 667 671
54. J. Wrammert, D. Koutsonanos, G.M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. Skountzou, M. Hornig, W.I. Lipkin, and et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection J. Exp. Med. 208 2011 181 193